Overexpression of wild-type c-RET and zero prevalence of RET/PTC rearrangements are associated with papillary thyroid cancer (PTC) in Kuwait

Experimental and Molecular Pathology

Volumn 90, Issue 1, 2011, Pages 61-65

  El Abdallah, Abir A ^a   Junaid, Thamradeen A ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

C RET; Papillary thyroid cancer; RET PTC

Indexed keywords

GENOMIC DNA; MESSENGER RNA; PROTEIN RET;

ANAPLASTIC CARCINOMA; ARTICLE; CARCINOGENESIS; CELL NUCLEUS; CONTROLLED STUDY; GENE FUNCTION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; KUWAIT; OVARY FOLLICLE CELL; PREVALENCE; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TOXIC GOITER; WILD TYPE;

GENE REARRANGEMENT; HUMANS; KUWAIT; PREVALENCE; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROID NODULE; THYROIDITIS, AUTOIMMUNE;

EID: 78650711754     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2010.10.002     Document Type: Article

References (36)

1. Blume-Jensen P., Hunter T. Oncogenic kinase signaling. Nature 2001, 411:355-365.
2. Cheung C., Ezzat S., Freeman J., Rosen I., Asa S. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod. Pathol. 2001, 14:338-342.
3. Chua E.L., Wu W.M., Tran K.T., McCarthy S.W., Lauer C.S., Dubourdieu D., Packham N., O'Brien C.J., Turtle J.R., Dong Q. Prevalence and distribution of RET/PTC 1, 2 and 3 in papillary thyroid carcinoma in New Caledonia and Australia. J. Clin. Endocrinol. Metab. 2000, 85(8):2733-2739.
4. Chung K.W., Chang M.C., Noh D.Y., Oh S.K., Choe K.J., Youn Y.K. RET oncogene expression of papillary thyroid carcinoma in Korea. Surg. Today 2004, 34:485-492.
5. DiFiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237:178-182.
6. Elisei R., Romei C., Vorontsova T., Cosci B. RET/PTC rearrangements in thyroid nodules: Studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J. Clin. Endocrinol. Metab. 2001, 86:3211-3216.
7. Eng C., Thomas G., Neuberg D., Mulligan L., Healey C., Houghton C., Frilling A., Raue F., Williams D., Ponder B. Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2007, 83:4310-4313.
8. Fedi P., Tronick S.R., Aaronson S.A. Growth factors. Cancer Medicine 1997, 41-64. Baltimore, MD, Williams and Wilkins. J.F. Holland, R.C. Bast, D.L. Morton, E. Frei, D.W. Kufe, R.R. Weichselbaum (Eds.).
9. Fischer A.H., Bond J.A., Taysavang P., Battles O.E., Wynford-Thomas D. Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. Am. J. Pathol. 1998, 153:1443-1450.
10. Fluge O., Haugen D., Akslen L., Marstad A., Santoro O., Fusco A., Varhaug J., Lillehaug J. Expression and alternative splicing of c-RET RNA in papillary thyroid carcinomas. Oncogene 2001, 20:885-892.
11. Fusco A., Santoro M. 20years of RET/PTC in thyroid cancer: Clinico-pathological correlations. Arq. Bras. Endocrinol. Metab. 2007, 51:731-735.
12. Hamatani K., Eguchi H., Ito R., Mukai M., Takahashi K., Taga M., Imai K., Cologne J., Soda M., Arihiro K., Fujihara M., Abe K., Hayashi T., Nakashima M., Sekine I., Yasui W., Hayashi Y., Nakachi K. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res. 2008, 68(17):7176-7182.
13. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
14. King Y.L., Chung Y.L., Po S.L. High prevalence of RET proto-oncogene activation (RET/PTC) in papillary thyroid carcinomas. Eur. J. Endocrinol. 2002, 147:741-745.
15. Klugbauer S., Lengfelder E., Demidchik E.P., Rabes H.M. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 1995, 11:2459-2467.
16. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. 2006, 6:292-306.
17. Learoyd D.L., Messina M., Zedenius J., Guinea A.L., Delbridge L.W., Robinson B.G. RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 1995, 83:3631-3635.
18. Lee C.H., Hsu L.S., Chi C.W., Chen G.D., Yang A.H., Chen J.Y. High frequency of rearrangement of the RET protooncogene RET/PTC in Chinese papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1998, 83(5):1629-1632.
19. Lee S., Hong S.W., Moon W.C., Oh M.R., Lee J.K., Ahn C.W., Cha B.S., Kim K.R., Lee H.C., Lim S.K. High prevalence of c-RET expression in papillary thyroid carcinoma from the Korean population. Thyroid 2005, 15(3):259-266.
20. Mayr B., Potter E., Goretzki P., Ruschoff J., Dietmaier W., Hoang-Vu C., Dralle H., Brabant G. Expression of RET/PTC1, -2, -3, -delta 3 and -4 in/German papillary thyroid carcinoma. Br. J. Cancer 1998, 77:903-906.
21. Namba H., Yamashita S., Pei H.C., Ishikawa N., Villadolid M.C., Tominaga T., Kimura H., Tsuruta M., Yokoyama N., Izumi M. Lack of PTC gene rearrangements in human thyroid tumors. Endocrinol. Jpn 1991, 38:627-632.
22. Nikiforov Y.E. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 2002, 13:3-16.
23. Park K.Y., Koh J.M., Kim Y.I., Park H.J., Gong G., Hong S.J. Prevalence of Gs alpha, Ras, p53 mutations and RET/PTC rearrangement in differentiated thyroid tumors in Korean population. Clin. Endocrinol. (Oxf) 1998, 49:317-323.
24. Rebelo S., Domingues R., Catarino A.L., Mendonηa E., Santos J.R., Sobrinho L. Immunostaining and RT-PCR: Different approaches to search for RET rearrangements in patients with papillary thyroid carcinoma. Int. J. Oncol. 2003, 23:1025-1032.
25. Rhoden K., Johnson C., Brandao G., Howe J., Smith B., Tallini G. Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Lab. Invest. 2004, 84:1557-1570.
26. Richardson D.S., Lai A.Z., Mulligan L.M. RET ligand-induced internalization and its consequences for downstream signaling. Oncogene 2006, 25:3206-3211.
27. Richardson D.S., Gujral T.S., Peng S., Asa S.L., Mulligan L.M. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins. Cancer Res. 2009, 69(11):4861-4869.
28. Santoro M., Melillo R.M., Calromagno F., Fusco A., Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann. NY Acad. Sci. 2002, 963:116-121.
29. Sugg S.L., Ezzat S., Rosen I.B., Freeman J.L., Asa S.L. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J. Clin. Endocrinol. Metab. 1998, 83:4116-4122.
30. Tallini G., Santoro M., Helie M., Carlomagno F., Salvatore G., Chiappetta G. RET/PTC oncogene activation defines a subset of papillary thyroid carcinoma lacking evidence of progression to poorly differentiated or undifferentiated tumor subtype. Clin. Cancer Res. 1998, 4:287-294.
31. Tallini G., Asa S.L. RET oncogene activation in papillary thyroid carcinoma. Adv. Anat. Pathol. 2001, 8:345-354.
32. Viglietto G., Chiappetta G., Martinez-Tello F.J., Fukunaga F.H., Tallini G., Rigopoulou D., Visconti R., Mastro A., Santoro M., Fusco A. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995, 21:1207-1210.
33. Wajjwalku W., Nakamura S., Hasegawa Y., Miyazaki K., Satoh Y., Funahashi H., Matsuyama M., Takahashi M. Low frequency of rearrangement of the RET and TRK proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn J. Cancer Res. 1992, 83:671-675.
34. Williams G.H., Roney S., Thomas G.A., Cummins G., Williams E.D. RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-n-polymerase chain reaction approach on archival-nested material. Br. J. Cancer 1996, 74:585-589.
35. Zou M., Shi Y., Farid N.R. Low rate of RET proto-oncogene activation (PTC/RETTPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer 1991, 73:176-180.
36. Zhu Z., Ciampi R., Nikiforova M.N., Gandhi M., Nikiforov Y.E. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 2006, 91:3603-3610.